This Week in Urology — Sep 18, 2026

Welcome to This Week in Urology. This week we're covering 10 notable papers spanning stone disease and lithotripsy technology, prostate cancer screening and diagnosis, and a cluster of surgical and functional urology studies that ask whether newer technique really beats older technique. Let's dive in.

We'll start with stones, where two trials this week land firmly in the "the shiny thing didn't change the outcome" category. In BJU International, Maciolek and colleagues report what they describe as the largest double-blind trial of its kind: a multicentre randomised study of 153 patients undergoing holmium laser lithotripsy for renal stones between 8 and 20 millimetres, with patients and surgeons blinded to whether Moses 2.0 pulse modulation was switched on [1]. Operative time was no different. Blinded video review found no difference in retropulsion. Complication rates and stone-free rates — roughly half in each arm — were comparable. What did differ was the surgeon. On the NASA Task Load Index, Moses was associated with lower mental, physical and temporal workload, less effort and less frustration, and higher self-rated performance. So the honest reading is that this technology is a surgeon-ergonomics intervention rather than a patient-outcomes intervention, which is not nothing, but it should reframe how it's marketed and how it's justified on a capital budget. Sitting alongside that, in World Journal of Urology, Yue and colleagues used propensity score matching in 436 patients undergoing percutaneous nephrolithotomy for 20 to 40 millimetre low-hardness stones, comparing ultrasonic lithotripsy with an integrated suction system against holmium laser [10]. Here the older, simpler modality won on day one: stone-free rates of about 96 percent versus about 85 percent, and complications — mostly low-grade Clavien one and two events — were roughly a third as common with ultrasonic lithotripsy. By one month the stone-free difference narrowed and was no longer statistically significant, and six-hour pain scores were modestly higher with ultrasound. This is retrospective and single-centre, but for soft, large-volume stones the suction-equipped ultrasonic device looks like the efficient choice, and the authors raise the prospect of stentless percutaneous surgery. Also in Urology, Tzeng and colleagues asked a question most of us answer by habit: when you start empiric medical prophylaxis without a metabolic abnormality to guide you, does it matter which drug you pick? Using a federated database of more than a hundred million patients and matching nearly 17,000 patients per arm, they found that patients started empirically on potassium citrate had a higher three-year risk of stone surgery than those started on a thiazide — about five and a half percent versus three and a half percent, so roughly a half-again increase in hazard, consistent across subgroups and after excluding crossover [2]. It's observational, residual confounding is inevitable, but if you reflexively reach for potassium citrate in the patient with no 24-hour urine data, this is a reason to reconsider.

Turning to prostate cancer, where the theme is precision — both at the population level and at the biopsy needle. In European Urology Focus, Carlsson and van den Bergh argue the pro position in a screening debate, and their central point is worth carrying into clinic: the real choice is no longer screening versus no screening, because PSA testing is already widespread and largely opportunistic [3]. They characterise that opportunistic status quo as a "Wild West" that is less effective at reducing prostate cancer mortality, consumes substantial resources, and entrenches socioeconomic disparities. Organised, risk-adapted screening, in their framing, is how you concentrate benefit and shrink overdiagnosis. That's an editorial position rather than new data, but it sets up the diagnostic paper nicely. In Urology, Britton and colleagues analysed just over 1,500 men with a positive MRI — PI-RADS three or above — who underwent both systematic and targeted biopsy [4]. Forty-three percent had grade group two or higher cancer. The question was whether PSA density and PI-RADS score could identify men who could safely skip systematic cores. The answer was no: omitting systematic biopsy altogether would have missed a quarter of all clinically significant cancers, and no combination of PI-RADS and PSA density brought that miss rate below five percent in any subgroup. But there is a useful, narrower message. In men with a solitary lesion, dropping the contralateral systematic cores would have missed significant cancer in only about one in forty patients — a plausible way to cut grade group one overdiagnosis while keeping nearly all the significant disease. That is a concrete, implementable change to biopsy templates. Staying with prostate cancer but moving to the operating room, Buhas and colleagues in World Journal of Urology describe a lower detrusor apron-sparing modification of robotic radical prostatectomy applied side-specifically according to oncological risk, in 167 men from a single surgeon [9]. Continence at zero to one pad was 85 percent at six weeks and essentially universal by two years; strict zero-pad continence was about half at six weeks rising to over ninety percent at a year. Positive margins were 16 percent overall, and five-year biochemical recurrence-free survival was 89 percent. The authors are appropriately restrained — there is no contemporaneous comparator, it's one surgeon, and they call it hypothesis-generating.

The third thread this week is a set of head-to-head comparisons in benign and functional urology, and the recurring finding is equivalence. In World Journal of Urology, Valdez-Gil and colleagues pooled seven comparative populations totalling around 3,500 patients comparing thulium fibre laser enucleation with conventional, non-Moses holmium enucleation of the prostate [6]. Thulium showed a statistically significant but roughly one-point advantage in International Prostate Symptom Score at three months, which the authors themselves call of uncertain clinical relevance. Flow-rate differences were small and inconsistent in direction across follow-up. Incontinence signals favouring thulium hinged on a single large registry cohort and disappeared when it was excluded. Certainty of evidence was mostly low or very low. The conclusion is that the two platforms are clinically comparable and selection should follow surgeon expertise and institutional resources, not marketing. In Neurourology and Urodynamics, the TRANSPER trial from Martínez-Cuenca and colleagues randomised 50 patients with pharmacologically refractory overactive bladder, double-blind, to twelve weekly sessions of percutaneous versus transcutaneous tibial nerve stimulation [8]. Both arms improved symptom severity and quality of life by similar margins, satisfaction was comparable at around two thirds of patients in each group, and transcutaneous stimulation was non-inferior on the primary outcomes. With fifty patients the trial is small and non-inferiority on that sample size should be read cautiously, but the implication — that a needle-free, potentially home-based option may serve for maintenance therapy — is worth testing in your own service. And rounding out the surgical technique group, Bieri and colleagues in World Journal of Urology randomised 40 patients to a novel transabdominal lumbar approach versus conventional retroperitoneal access for robot-assisted renal surgery [7]. The new approach cut median time from skin incision to renal artery identification by 16 minutes, from 54 to 38, with comparable perioperative safety. It's a single-centre trial of forty patients with a technique-oriented endpoint rather than a patient-centred one, so treat it as proof of concept.

If you only have time for one paper this week, make it the Journal of Urology study from Matulewicz and colleagues on bladder cancer incidence after microhematuria [5]. Among more than 267,000 Veterans Health Administration patients with new microhematuria, only about one in eight completed cystoscopy within two years, and bladder cancer was diagnosed in about one and a half percent. Critically, a simple model built from age, sex, smoking history and red cell count outperformed the American Urological Association risk stratification, which performed close to chance. That directly challenges how we triage one of the highest-volume referrals in urology, and it identifies meaningful risk gradients even within the guideline-defined high-risk group.

Here are the key takeaways from this week in Urology. First, Moses 2.0 did not shorten operative time, reduce retropulsion, or improve stone-free rates in a blinded randomised trial — its measurable benefit was to surgeon workload [1]. Second, for empiric stone prophylaxis without metabolic data, thiazides were associated with meaningfully fewer subsequent stone surgeries than potassium citrate [2]. Third, in men with a positive MRI, you cannot safely abandon systematic biopsy on the basis of PI-RADS and PSA density, but dropping contralateral cores for a solitary lesion misses very little significant disease [4]. Fourth, current guideline risk stratification for microhematuria discriminates barely better than chance, and readily available clinical variables do better [5]. And fifth, thulium fibre and holmium enucleation of the prostate, and percutaneous versus transcutaneous tibial nerve stimulation, are each essentially interchangeable on current evidence — so choose on cost, access, and expertise [6], [8].

That's your roundup for This Week in Urology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And a quick rating on Apple Podcasts or Spotify helps other physicians discover the show.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.